What is the recommended dosing conversion from Ozempic (semaglutide) 1 mg to Mounjaro (tirzepatide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting Ozempic 1 mg to Mounjaro Dosing

When converting from Ozempic (semaglutide) 1 mg weekly to Mounjaro (tirzepatide), the recommended equivalent starting dose is 5 mg of tirzepatide weekly, with titration to higher doses as needed for optimal glycemic control.

Rationale for Conversion

Ozempic (semaglutide) and Mounjaro (tirzepatide) are both injectable medications for type 2 diabetes, but they have different mechanisms of action:

  • Ozempic is a GLP-1 receptor agonist
  • Mounjaro is a dual GIP/GLP-1 receptor agonist with potentially greater efficacy

Dosing Comparison

Based on the available evidence, here's how the medications compare:

Medication Available Doses Maximum Approved Dose
Ozempic (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 2 mg weekly 2 mg weekly [1]
Mounjaro (tirzepatide) 2.5 mg, 5 mg, 10 mg, 15 mg weekly 15 mg weekly [1]

Conversion Protocol

  1. Initial Conversion: Start with tirzepatide 5 mg once weekly when converting from semaglutide 1 mg

    • This provides a clinically appropriate starting point based on comparative efficacy data 2, 3
  2. Dose Titration:

    • After 4 weeks on 5 mg, consider increasing to 10 mg weekly if additional glycemic control is needed
    • After another 4 weeks, may increase to maximum dose of 15 mg weekly if needed
  3. Monitoring: Assess glycemic response and tolerability at each dose level before titrating up

Evidence for Efficacy Comparison

Clinical trials directly comparing these medications show:

  • Tirzepatide demonstrated superior glycemic control compared to semaglutide in head-to-head trials 2
  • The SURPASS-2 trial showed tirzepatide at all doses (5 mg, 10 mg, 15 mg) was superior to semaglutide 1 mg for HbA1c reduction 2
  • Mean HbA1c reductions were:
    • Tirzepatide 5 mg: -2.01%
    • Tirzepatide 10 mg: -2.24%
    • Tirzepatide 15 mg: -2.30%
    • Semaglutide 1 mg: -1.86%

Important Clinical Considerations

  • Gastrointestinal Side Effects: Both medications commonly cause GI effects (nausea, vomiting, diarrhea), but tirzepatide may have slightly higher rates, especially at higher doses 2, 3
  • Hypoglycemia Risk: Low risk with both medications when used as monotherapy, but monitor if combined with insulin or sulfonylureas
  • Cost Considerations: Both medications have similar cost profiles according to AWP/NADAC data 1

Common Pitfalls to Avoid

  1. Skipping Titration: Do not start directly at higher tirzepatide doses (10 mg or 15 mg) when converting from semaglutide, as this increases risk of GI side effects

  2. Overlapping Medications: Discontinue semaglutide before starting tirzepatide to avoid duplicate incretin effects

  3. Inadequate Monitoring: Both medications have long half-lives (approximately 5-7 days), so effects of dose changes may not be immediately apparent

In summary, when converting from Ozempic 1 mg to Mounjaro, start with 5 mg weekly of tirzepatide and titrate as needed based on glycemic response and tolerability.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.